Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Chondrosarcoma

• Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
• Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
• CD30biAb-AATC for CD30+ Malignancies
• A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
• A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
• IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
• Study of INBRX-109 in Conventional Chondrosarcoma
• Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers
• Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
• Testing Atezolizumab in Patients >= 2 Years Old With Newly Diagnosed, Unresectable, or Metastatic Clear Cell Sarcoma or Chondrosarcoma
• Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
• Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
• AG-120 in People With IDH1 Mutant Chondrosarcoma
• Apatinib for Inoperable Advanced Chondrosarcoma
• Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
• A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
• Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
• Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
• Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
• A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
• Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
• Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum
• Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
• Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
• A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
• Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
• Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
• Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
• SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
• A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas
• IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
• Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
• Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
• Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
• Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
• A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
• Vismodegib in Treating Patients With Advanced Chondrosarcomas
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
• Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
• A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
• Trial of Dasatinib in Advanced Sarcomas
• A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
• Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
• S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma
• Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
• S9624 Ifosfamide in Treating Patients With Meningeal Tumors